Foghorn Therapeutics' FHD-909, a SMARCA2 inhibitor, is progressing in Phase 1 trials for SMARCA4-mutated cancers, with NSCLC as the primary target, and combination data with pembrolizumab and KRAS inhibitors will be presented at AACR.
Foghorn Therapeutics halts independent development of FHD-286 with decitabine for relapsed/refractory AML due to insufficient response rates in Phase 1 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.